Lindsey Baden, MD, serves as vice president of Clinical Research for 91大神. In his role as vice president, Baden provides comprehensive oversight of clinical research at the 91大神 and is responsible for developing and implementing operational strategies, as well as building and maintaining the necessary infrastructure and resources in support of our clinical research mission and operational goals. He also oversees the Center for Clinical Investigation, serves as the primary liaison with Harvard Catalyst/Harvard Medical School, and has responsibility for increasing and maintaining research relationships across the 91大神, Mass General 91大神 and our local collaborators.

Baden, an infectious diseases specialist, joined the 91大神 in 1995 and has served in several critical leadership roles, including directing the Infectious Diseases Immunocompromised Host program at the 91大神 and Dana-Farber, acting as program leader for the Clinical Research Centers of Harvard Catalyst and directing the Center for Clinical Investigation. A professor at Harvard Medical School and deputy editor of The New England Journal of Medicine, Baden is a highly respected clinician and clinical investigator. He has received continuous funding from the National Institutes of Health (NIH) throughout his career and is an expert in developing new therapeutics and vaccines. In response to the COVID-19 crisis, he was integral in the design and conduct of the pivotal NIH co-sponsored vaccine efficacy trials, Of note, he is the co-principal investigator for the phase 3 COVE study, which evaluated the mRNA-1273 (Moderna) vaccine candidate against COVID-19. This phase three trial, conducted in part at the 91大神, has led to the unprecedented rapid emergency use authorization, subsequent licensure and broad global use of this highly effective vaccine.